ReCode Therapeutics

Home
United States
Menlo Park, CA
ReCode Therapeutics

ReCode Therapeutics is a clinical-stage genetic medicines company powering the future of genetic medicines with precision delivery.

10/01/2025

Clinical research for cystic fibrosis depends on the strength of the CF community. Every participant, caregiver, and healthcare provider plays a role in moving us forward. ReCode’s clinical study of an inhaled mRNA therapy is an opportunity to stand together in the fight against CF and build a brighter future for everyone affected.

Be a part of the future in CF treatment—learn more about our study at Cf-clinical-studies.com

09/29/2025

Today, ReCode Therapeutics announced it has secured more than $29 million in financing to advance our genetic medicines pipeline. This update includes expanded support from the , with $3 million in new funding to support the ongoing Phase 2 clinical trial of RCT2100, our investigational inhaled mRNA therapy for cystic fibrosis.

We also announced a new research collaboration with to identify and develop lipid nanoparticle formulations that improve the delivery of antisense oligonucleotides (ASOs) to underexposed regions of the brain.

Finally, our leadership team, including Dr. Jessica Couch and Dr. John Matthews, Chief Medical Officer, looks forward to connecting with colleagues and the community at the European Respiratory Society Congress ( ) in Amsterdam this week, and later this month at the North American Cystic Fibrosis Conference ( ) in Seattle.

09/26/2025

Our Chief Medical Officer, John Matthews, and Chief Scientific Officer, Jessica Couch, will attend the
(ERS) Congress 2025 in Amsterdam, September 27–October 1.

This year’s theme, “Respiratory health around the globe,” aligns with our mission to advance genetic medicines for serious respiratory diseases like cystic fibrosis.

If you’re attending ERS, reach out today to schedule time with John and Jessica.

09/25/2025

On World Lung Day, we recognize the essential role lung health plays in overall well-being and the need for continued progress in respiratory care.

At ReCode, we are advancing treatments for cystic fibrosis, focusing on those who need new options. Our Selective Organ Targeting (SORT) LNP platform is designed to deliver genetic medicines directly to the lungs with precision. This approach reflects our commitment to transforming what is possible for the respiratory community.

09/23/2025

ReCode’s Phase 1b clinical study for cystic fibrosis uses cutting-edge mRNA therapy to tackle CF at its genetic roots. This investigational approach is designed for people with certain CFTR mutations, using our Selective Organ Targeting (SORT) Lipid Nanoparticle (LNP) platform for targeted delivery to lung cells.

Learn more at Cf-clinical-studies.com

09/17/2025

Living with cystic fibrosis is a daily challenge. From managing medications to monitoring lung health, it can feel like an uphill journey. However, through clinical studies, we have the chance to change the future of CF treatment and make a lasting difference for the CF community.

Learn more about a clinical study for CF here: Cf-clinical-studies.com

09/15/2025

We are pleased to announce that Jessica Couch has been named Chief Scientific Officer (CSO) of ReCode Therapeutics. Jessica has been a driving force within our organization, combining deep scientific expertise with a thoughtful, collaborative approach to leadership. She has a gift for uniting teams around a shared vision and turning bold ideas into progress for patients.

As CSO, Jessica will lead our research organization and guide the advancement of our pipeline of disease-modifying mRNA and gene correction therapeutics. Her experience and dedication will play a major role in shaping the future of our science and impact.

Please join us in congratulating Dr. Couch on her well-deserved appointment!

09/12/2025

Congratulations to ReCode Scientific Advisory Board (SAB) member Dr. Eric Olson, Ph.D., on being awarded the 2025 Louisa Gross Horwitz Prize from University. This prestigious honor recognizes his pioneering research in muscle biology and genetic medicine, advancing the understanding of Duchenne muscular dystrophy (DMD) and laying the groundwork for new therapeutic approaches for patients.

Dr. Olson’s scientific leadership continues to inspire the field of genetic medicine and accelerate progress in rare diseases. We are grateful for his guidance as a member of our SAB, where his expertise helps inform our work on our Cystic Fibrosis program and advance our mission to deliver new possibilities for patients with rare diseases.

09/08/2025

Did you know that about 10% of people with cystic fibrosis have genetic changes that current treatments can’t address? These specific changes prevent the production of the CFTR protein, which is essential for current therapies to work. We’re working on an investigational therapy designed to help this group within the CF community.

Learn more about the RCT2100 clinical study and our investigational therapy via the link in our bio.

09/04/2025

Yesterday in New York City, our CEO Shehnaaz Suliman moderated “Perspectives on Navigating Uncertainty at the FDA” at the Biotech CEO Sisterhood Forum hosted by J.P. Morgan.

With:
Julie Tierney — Leavitt Partners
Brad Zakes — Biotechnology Innovation Organization (BIO)
Jevan Jammal — No Patient Left Behind
Emily Minkow — RA Capital Management

This conversation brought together leaders from across the industry to examine how policy, science, and patient needs intersect, and how companies can navigate this landscape to bring innovative therapies to patients faster and responsibly.

We’re grateful to J.P. Morgan and the Biotech CEO Sisterhood for creating a forum for these important discussions, and to the fellow panelists who brought their thoughtful insights and perspectives.

09/01/2025

This Labor Day, we recognize the people whose work powers progress. From the labs advancing breakthrough science to the many roles that make innovation possible. Biotechnology thrives on collaboration and resilience. Every discovery and advancement reflects shared effort and commitment.

Labor Day is also a reminder of our responsibility to create a workplace where every perspective matters, every voice is heard, and opportunity is accessible to all. At ReCode, this shapes how we work each day, because science advances when inclusion is part of the design.

Here’s to the people driving impact today and shaping a healthier tomorrow. And here’s to weathering extraordinary headwinds and staying the course to make the difference we all hope to make!

08/18/2025

About 10% of the CF community has genetic mutations that do not benefit from existing therapeutics. Despite the availability of CFTR modulators that work for 90% of people with cystic fibrosis, many will not be able to take the medication due to side effects, lack of response, or other reasons.

Learn more about a clinical study investigating a treatment for this 10% of people with CF via the link in our bio.

Address

1140 O'Brien Drive
Menlo Park, CA
94025

Telephone

+14085851700

Website

https://recodetx.com/

Alerts

Be the first to know and let us send you an email when ReCode Therapeutics posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to ReCode Therapeutics:

Shortcuts

Want your practice to be the top-listed Clinic in Menlo Park?